WE CLAIM:

1. A pharmaceutical composition comprising:

(I) at least one oxazole compound selected from the group consisting of 2,3-dihydro-6-nitroinidazo[2,1-b]oxazole compounds represented by general formula (1), optically active isomers thereof, and pharmacologically acceptable salts thereof;

general formula (1):



(1)

wherein R^1 represents a hydrogen atom or C_{1-6} alkyl group, n represents an integer from 0 to 6, and R^2 represents any of the groups of general formula (A) to (F) below;

groups represented by general formula (A):



(A)

wherein R^3 represents any of the groups (1) to (6) shown below:

(1) phenoxy groups, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups;

(2)phenyl C_{1-6} alkoxy groups, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups;

(3) $-NR^4R^5$ groups, wherein R^4 represents a C_{1-6} alkyl group, and R^5 represents a phenyl group, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups;

(4) phenyl C_{1-6} alkyl groups, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups;

(5) phenoxy Cl-6 alkyl groups, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups; and halo-substituted or unsubstituted C_{1-6} alkoxy groups; and

(6) benzofuryl C_{1-6} alkyl groups, optionally substituted on the benzofuran ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups;
groups represented by general formula (B):



(B)

wherein R^6 represents a phenyl group, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups;
groups represented by general formula (C):



(C)

wherein R^7 represents a phenyl C_{2-10} alkenyl group, optionally substituted on the phenyl ring with one or more member selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups, or represents a biphenyl C_{1-6} alkyl group, optionally substituted on one or both phenyl rings with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups;
groups represented by general formula (D):



(D)

wherein R^8 represents a phenyl C_{1-6} alkyl group, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C_{1-6} alkyl groups, and halo-substituted or unsubstituted C_{1-6} alkoxy groups;
groups represented by general formula (E):



(E)

wherein R^8 is the same as above; and

groups represented by general formula (F):



(F)

wherein R^8 is the same as above; and

(II) at least one cellulose compound selected from the group consisting of hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate, wherein the proportion of ingredient (II) to ingredient (I) in the pharmaceutical composition is 0.5 to 15 parts by weight per part by weight of ingredient (I).

2. The pharmaceutical composition as claimed in claim 1, wherein the oxazole compound is 2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole.

3. The pharmaceutical composition as claimed in claim 1, wherein the oxazole compound is 6-nitre-2-{4-[4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole.

4. The pharmaceutical composition as claimed in claim 1, wherein the oxazole compound is 2-methyl-6-nitro-2-(4-{4-[3-(4-trifluoromethoxyphenyl)-2-propenyl]piperadin-1-yl}phenoxymethyl)-2,3-dihydroimidazo[2,1-b]oxazole.

5. The pharmaceutical composition as claimed in claim 1, wherein the oxazole compound is 2-methyl-6-nitre-2-{4-[4-(4-trifluoromethylphenoxymethyl)piperidin-1-yl]phenoxymethyl}-2.3-dihydroimidazo[2,1-b]oxazole.

6. The pharmaceutical composition as claimed in any one of claims 1 to 5, optionally comprising vitamin E, wherein the proportion of vitamin E to ingredient (I) in the pharmaceutical

composition is 0.001 to 1 parts by weight per part by weight of ingredient (I).

7. The pharmaceutical composition as claimed in claim 6, wherein the vitamin E is dl-α-tocophenol.

Dated this 18th day of December, 2007.

Neha Srivastava

[NEHA SRIVASTAVA]
OF REMFRY & SAGAR
ATTORNEY FOR THE APPLICANT[S]